Background Antihistone antibodies (AHA) have been linked to Drug-Induced Lupus Erythematosus (DILE) for decades1. However, for some authors this relationship is not so clear and sugest that the presence of these autoantibodies is related to other autoimmune diseases more frequently2,3,4.
Objectives The main objetive of this work was to study the association of AHA with different autoimmune entities (including DILE) and secondarily, look into which clinical manifestations and which autoantibodies are more frequently related to AHA.
Methods We performed a descriptive study. A database was constituted using all patients with AHA+ in any blood analysis between years 2000 and 2016 in the University Hospital Complex of Vigo. The variables of the study were: presence of autoimmune disease, clinical manifestations and related autoantibodies.
ResultsNone of the 73 patients AHA+ developed DILE while almost the 50% of them suffer any other autoimmune disease. We found a high percentage of AHA+ patients with lupus erythematous complications such as arthritis and hematological abnormalities. AntiDNAds antibody was the more frequent coexpressed autoantibody.
AHA detection is not useful as DILE screening.
AHA+ sugest the presence of other autoimmune disease rather than DILE.
AHA+ may be related to lupus erythematous systemic complications.
Fritzler MJ, Tan EM. Antibodies to histone in drug-induced and idiopathic lupus erythematosus. J Clin Invest. 1978;62:560–567.
Peng SL, Craft J. Antinuclear antibodies. In: Ruddy S, Harris ED, Sledge CB, eds. Kelley's Textbook of Rheumatology. 6th ed. Philadelphia, Pa: WB Saunders; 2001:166.
Kubo M, Ihn H, Yasawa N, et al. Prevalence and antigen specificity of antihistone antibodies in patients with polymyositis/dermatomyositis. J Invest Dermatol. 1999;112:711–715.
Zirwas MJ, Kress DW, Deng JS. The Utility of Antihistone Antibody Screening in the Diagnosis of Drug-Induced Lupus Erythematosus. Arch Dermatol Apr 2004; VOL 140: 494–495.
Disclosure of Interest None declared
Statistics from Altmetric.com
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.